PBENZ-DBRMD is a first-in-class inhibitor of enzyme iodothyronine deiodinase type 3 (DIO3) with antitumor effects both in vitro and in vivo.
PBENZ-DBRMD demonstrated attenuated cell counts, induction in apoptosis, and a reduction in cell proliferation in DIO3-positive HGSOC cells (OVCAR3 and KURAMOCHI), but not in DIO3-negative normal ovary cells (CHOK1) and OVCAR3 depleted for DIO3 or its substrate, T3.
